Efgartigimod in refractory autoimmune myasthenia gravis.
Linda Remijn-NelissenMartijn R TannemaatAnnabel M RuiterYvonne J M CampmanJan J G M VerschuurenPublished in: Muscle & nerve (2024)
In patients with refractory MG, efgartigimod was effective for at least half of all patients. Patients required more frequent dosing compared to the ADAPT phase 3 trial. In 80% of the patients concurrent medication could be reduced or discontinued.